Request Demo
Radiopharmaceutical outfit Lantheus mulls potential $7B takeover by Curium: Bloomberg
AcquisitionDrug Approval
Lantheus reported $377.3 million in worldwide revenues over the first quarter of 2026, reflecting sales of its roster of radiodiagnostic imaging agents.
Lantheusbillion-dollar acquisition within the radiopharmaceutical space could be percolating as Lantheus Holding considers a buyout offer from Curium Pharma, Bloomberg reported on Friday.
Curium’s proposal values Massachusetts-based Lantheus at about $7 billion, the news outlet said,Lantheus Holdingamiliar with the matter. The deCurium Pharmaeeks away, but a final discussion has not yet been made and no agreement is guaranteed, according to Bloomberg.
Curiumus does “not comment on market rumors or speculation” as a matter of policy, a spokesperson told Fierce Pharma on Tuesday.
Lantheuspart, Curium “operates in a highly competitive environment and, like all companies, is always evaluating organic and external pathways to better serve our patients and customers,” a company representative said in an emailed statement. At the same time, the representative also caveated to Fierce that Curium “does not comment on market rumors or speculation.”
Last year, CurCuriumd a hand in what was the “largest transaction in nuclear medicine globally” when its majority owner, global investment firm CapVest, raised money to recapitalize Curium through a new continuation vehicle that similarly valued the radiopharmaceutical company at $7 billion. The investor basCurium chipped in reflected a “strong belief in the future trajectory of the company in a market poised for exponential growth in the next 15 years,” Curium said at the time.
Lantheusst year, the radiopharmaceutical specialist shelled out $250 million in upfront cash to take on Evergreen Theragnostics, committing up to $752.5 million in additional potential milestone payments. The union of Evergreen’s manufacturing capabilities and infrastructure with Lantheus’ radiopharmaceutical digs was meant to help the company “meet the complex demands of radiopharmaceutical development and production,” Lantheus said, and it also adds new candidates to the company's oncology diagnostic pipeline.
Other recent acquisitions for Lantheus include Meilleur Technologies and its Alzheimer’s disease PET imEvergreen TheragnosticsMolecular Imaging and its approved F-18 PET imaging agent Neuraceq, along with broader AlzhEvergreenadiodiagnostic commercial infrastructure.LantheusLantheus
While being “disciplined in ouLantheusl deploymMeilleur Technologies radiodiagAlzheimer’s diseaseing the “best path to maximize value from our radiotherapeutic asF-18,” Lantheus is lookNeuraceqlay the groundwork for growth acceleration beginning in 2027,” interim CEO Mary Anne Heino said in the company’s first quarter earnings release. The radiopharma reported $377.3 million in worldwide revenues over the first quarter of 2026, backed largely by Neuraceq, the ultrasound-enhancing agent Definity and the prostate cancer diagnostic imaging agent Pylarify.
Meanwhile, next month will see the expiration of a 30-month stay that will allow for approval of Lantheus' radioequivalent version of Novartis’ gastroenteropancreatic neLantheusrine tumor-fighting Lutathera, which the FDA granted a tentative approval in March.NeuraceqDefinityprostate cancerPylarify
Radiopharmaceuticals, or drugs made using small amounts of radioactive material, have quickly risLantheuspularity. Just last week, radNovartise gastroenteropancreatic neuroendocrine tumormillion faLutathera Lansing, MiFDAgan, that will see multiple superconducting linear accelerators and state-of-the-art processing and quality systems to facilitate the increased production of alpha-emitting isotope Actinium-225 (Ac-225).
The class of nuclear medicines can be used in both therapeutic and diagnostic roles.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!